General Information About Hepatitis C Drugs

• Hepatitis C Medications – The page has links to fact sheets and articles on individual hepatitis C drugs and drug combinations.
• Patient Assistance Programs – This fact sheet from HCV Advocate is a valuable resource for people hoping to access the hepatitis C treatment and for the providers who serve them.
• Help with Medicines – This one-page, easy-to-read fact sheet on patient assistance programs (PAPs) designed for patients.

Health Library Pages About FDA-Approved Hepatitis C Drugs and Combination Pills

• Boceprevir (Victrelis)
• Daclatasvir (Daklinza)
• Interferon (Pegasys, PEG-interferon alfa, PegIntron, pegIFN alfa)
• Ribavirin (Copegus, RBV, Rebetol, Ribasphere)
• Simeprevir (Olysio)
• Sofosbuvir (Sovaldi)
• Telaprevir (Incivek, Incivo)
• Harvoni (Sofosbuvir + Ledipasvir)
• Viekira Pak (Ombitasvir + Paritaprevir + Ritonavir + Dasabuvir)
• Technivie (Ombitasvir + Paritaprevir + Ritonavir)
• Zepatier (Elbasvir + Grazoprevir)
• Epclusa (Sofosbuvir + Velpatasvir)

Selected Recent Articles

Note: The treatment for persons living with chronic hepatitis C virus (HCV) infection is evolving very rapidly. Many articles and reports about HCV treatments are being published each year, and HCV treatment information becomes outdated quickly.  This web page contains links to news about HCV treatment that involves drugs that have already been approved by the U.S. Food and Drug Administration.  For articles and reports about research into experimental HCV drugs that have not yet been approved, please see the Library’s “Hepatitis C: New and Experimental Treatments” web page.

Many of the articles below come from several reliable sources: AIDSmap)com, Hepmag)com, and TheBody. For additional articles from other reliable sources, you can do searches on the following sites: HCVAdvocate, HIVandhepatitis, Infohep, and NATAP.

• EASL issues new hepatitis C treatment recommendations for all genotypes.  (September 2016, AIDSmap)
• Epclusa demonstrates manageable drug interaction profile with commonly used ART.  (September 2016, Healio)
• Hepatitis C Cure Rates High With Daclatasvir/Sofosbuvir Regardless of Antiretroviral Regimen.  (September 2016, TheBodyPro)
• New Guidelines Recommend Hep B Testing Before Hep C Treatment.  (September 2016, Hepmag)
• Real-World Hepatitis C Cure Rates Higher with 2 Direct Acting Agents.  (September 2016, TheBodyPro)
• Excellent Hepatitis C Cure Rate for Just Eight Weeks of Harvoni.  (August 2016, Poz)
• The Future of Hepatitis C Treatment.  (September 2016, TheBodyPro)
• 8-week Harvoni safe, effective in patients coinfected with HIV/HCV.  (September 2016, Healio)
• Direct-acting antiviral ‘revolution’ improves treatment of HIV/HCV coinfection.  (August 2016, Healio)
• Hepatitis C Treatment Epclusa Works Well in Those With HIV.  (July 2016, Poz)
• FDA Approves Once-Daily Hepatitis C Regimen Viekira XR.  (July 2016, Hepmag)
• How Will Gilead’s Epclusa Change the Hepatitis C Treatment Landscape? (July 2016, Hepmag)
• Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection study. (July 2016, AIDSmap)
• FDA approves Epclusa for treatment of chronic Hepatitis C virus infection.  (June 2016, FDA); related coverage from Hepmag, MedPage Today, FDA Beta Blog, and NEJM Journal Watch
• Ribavirin Concentrations Are Often Off in Those Treated for Hepatitis C.  (June 2016, Hepmag)
• Sofosbuvir/Daclatasvir Cures Advanced HCV in 100% of HIV Group.  (June 2016, TheBodyPro)
• Among Those With HIV and Hep C, Real-World Harvoni Results Mirror Clinical Trial.  (May 2016, Hepmag)
• Generic hep C drugs as effective as high-cost brand names, plus other European Liver Conference highlights.  (May 2016, Beta Blog)
• Harvoni leads to high real-world virologic response rates in HIV/HCV coinfection.  (May 2016, Healio)
• EASL 2016 Roundup: The big news from the recent European liver conference.  (May 2016, Poz)
• WHO issues new hepatitis C guidelines, EASL guidelines update forthcoming in September.  (May 2016, AIDSmap)
• AbbVie’s Viekira Pak Works Just As Well in Those with Hepatitis C Drug Resistance.  (April 2016, Hepmag)
• DAAs achieve excellent outcomes in real-world settings.  (April 2016, AIDSmap)
• Excellent Real-World Results for AbbVie’s Hepatitis C Regimen Viekira Pak.  (April 2016, Hepmag)
• Generic Hepatitis C Drugs Appear Highly Effective.  (April 2016, Hepmag)
• Studies to Begin of $300 Generic Hepatitis C Treatment for International Use.  (April 2016, Poz)
• Another Study Finds Six Weeks of Harvoni Can Cure Acute Hep C.  (April 2016, Hepmag)
• Low-cost generic hepatitis C drugs match branded products in viral response.  (April 2016, AIDSmap)
• Six weeks of sofosbuvir/ledipasvir is enough to cure acute hepatitis C in HIV-negative people.  (April 2016, AIDSmap)
• Mathematical Model Predicts Who Can Stop Hepatitis C Treatment Early.  (March 2016, Hepmag)
• Eight Weeks of Harvoni Works Well in the Real World, Even in Some Not Approved for Such Short Treatment.  (March 2016, Poz)
• U.S. physicians slowly greet new hepatitis C treatment Zepatier. (March 2016, Hepmag)
• Harvoni effective for patients with HIV, acute HCV.  (February 2016, Healio); related coverage from AIDSmap and Poz
• AbbVie Hep C Regimen Clashes With Some HIV Protease Inhibitors.  (February 2016, Poz)
• FDA Expands Daklinza/Sovaldi Approval to Include Treatment of Hepatitis C Genotype 1.  (February 2016, Poz)
• Zepatier: Frequently Asked Questions.  (February 2016, Project Inform)
• New Merck combination pill Zepatier approved for hepatitis C treatment in the United States.  (February 2016, AIDSmap)
• Elbasvir/Grazoprevir (Zepatier) Combination Pill for HCV a Welcome New Option – With a Few Buts.  (January 2016, Journal Watch)
• FDA Approves Zepatier for Treatment of Chronic Hepatitis C Genotypes 1 and 4.  (January 2016, U.S. Food and Drug Administration)
• Which Hepatitis C Treatment to Start in 2016.  (January 2016, TheBodyPro)
• Sofosbuvir/daclatasvir combination could be produced for $200 per hepatitis C cure.  (December 2015, AIDSmap)
• Success in Adding Sovaldi to Hep C Re-treatment Regimens.  (December 2015, Hepmag)
• Study reveals potential challenges for scaling up of HCV therapy in UK.  (November 2015, AIDSmap)
• Daclatasvir and sofosbuvir with ribavirin cures 90% of people with genotype 3 hepatitis C.  (November 2015, AIDSmap)
• Daclatasvir plus sofosbuvir works well for people with genotype 3 hepatitis C and advanced liver disease in real-world clinical practice.  (November 2015, AIDSmap)
• Daklinza & Sovaldi Better Treats Those With HIV & HCV.  (November 2015, Hepmag)
• Excellent Real-World Results for 8 Weeks of Hep C Treatment Harvoni.  (November 2015, Hepmag)
• Treatment intensification with sofosbuvir permits cure after failure of previous HCV treatment.  (November 2015, AIDSmap)
• Fast Responders May Only Need 3 Weeks of Triple Hep C Therapy.  (November 2015, Hepmag)
• High Hep C Cure Rates for Viekira Pak in Ongoing Liver Safety Study.  (November 2015, Hepmag)
• FDA OKs Harvoni for Hep C Genotypes 4, 5, 6, People with HIV.  (November 2015, Hepmag)
• Gilead Seeks FDA Approval for Hep C Treatment for All Genotypes.  (October 2015, Hepmag)
• Sofosbuvir/ledipasvir for 8 weeks cures most hard-to-treat hepatitis C patients in real-world study.  (October 2015, AIDSmap)
• Hepatitis C Treatments Viekira Pak and Technivie May Cause Liver Damage.  (October 2015, Hepmag)
• FDA Warns of Serious Liver Injury Risk with Hepatitis C Treatments Viekira Pak and Technivie.  (October 2015, the FDA and TheBodyPro)
• Sofosbuvir + daclatasvir demonstrates high cure rates for people with HIV and HCV co-infection.  (October 2015, AIDSmap)
• Interferon-free treatment works well for people who inject drugs, but barriers to access remain.  (October 2015, AIDSmap)
• Interferon Era Saw Low HCV Therapy Rates in Swiss People With HIV.  (September 2015, Poz)
• Hep C Treatment Viekira Pak Works Well in Real World.  (September 2015, Hepmag)
• Sovaldi-Based Hep C Regimens Less Successful in Real World.  (September 2015, Poz)
• Harvoni Sees Near-Perfect Cure Rate for Hep C Genotype 4.  (August 2015, Hepmag)
• Continuing Changes in the Hepatitis C Treatment Landscape.  (August 2015, Hepmag)
• Up to Three-Quarters May Need HIV Regimen Switch When Starting HCV Treatment.  (August 2015, TheBodyPro)
• New Hep C Drugs Cure High Rates of People Coinfected With HIV.  (August 2015, Poz)
• Daklinza/Sovaldi Success for Those With HIV/HCV.  (August 2015, Poz)
• Interferon-free hepatitis treatment is highly effective for people with HIV and HCV co-infection in three studies.  (July 29,2015, AIDSmap)
• FDA Green Lights AbbVie’s Technivie for Genotype 4 of Hepatitis C.  (July 2015, Hepmag)
• FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3.  (July 2015, Hepmag)
• Japan Approves Harvoni After Study Shows 100% Cures.  (July 2015, Hepmag)
• Preventing and treating viral hepatitis in people living with HIV is key focus of IAS 2015.  (July 2015, International AIDS Society)
• Genotype 5.  (July 2015, Hepmag)How Sure Is a Cure?  (July 2015, Hepmag)
• Genotype 3 [treatment]: An Unmet Need for Some.  (July 2015, Hepmag)
• Viekira Pak Cures Hep C in 100% of Cirrhotic Genotype 1bs.  (July 2015, Hepmag)
• Hepatitis C Treatment: Hepatitis C Medications.  (June 2015, Hepmag)
• Curing Hard-to-Treat Hepatitis C.  (June 2015, TheBodyPro)
• Harvoni and Sovaldi/Daclatasvir Safer to Mix With HIV Meds.  (June 2015, Poz)
• 8 Weeks of Daclatasvir/Sovaldi Cures Some With HCV/HIV.  (June 2015, Hepmag)
• Sofosbuvir plus daclatasvir for 12 weeks cures most HIV/HCV coinfected patients.  (June 2015, AIDSmap)
• Preparing for Hepatitis C Treatment: Part 2.  (June 2015, Hepmag)
• Harvoni added benefit for patients with HCV/HIV coinfection.  (May 2015, Healio)
• Harvoni Boasts Near-Perfect Hep C Cure Rates in Cirrhotics.  (May 2015, Hepmag)
• Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis.  (May 2015, AIDSmap)
• Daclatasvir and Sovaldi Cure High Rates of Genotype 1 of Hep C.  (May 2015, Hepmag)
• VIDEO: Expert discusses emerging viruses, hepatitis C treatment, HIV prophylaxis.  (May 2015, Healio)
• Oral DAAs effective for HIV/HCV patients.  (May 2015, Healio)
• Preparing for Hepatitis C Treatment: Part 1 – by Alan Franciscus.  (May 2015, Hepmag)
• Putting Off Hep C Treatment Raised Risks With Older Treatments.  (May 2015, Hepmag)
• Retreatment With 24 Weeks of Harvoni Often Cures Hepatitis C.  (May 2015, Hepmag)
• Success for 8 Weeks of Grazoprevir/Elbasvir Plus Sovaldi.  (May 2015, Hepmag)
• Viekira Pak Shows Promise for Kidney-Impaired People With Hep C.  (May 2015, Hepmag)
• When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration.  (May 2015, AIDSmap)
• Sofosbuvir-based treatment safe and effective in advanced kidney disease.  (April 2015, AIDSmap)
• Options for Treating Hepatitis C in Those with Advanced Cirrhosis.  (April 2015, Hepmag)
• Sofosbuvir plus pegylated interferon/ribavirin is highly effective for people with hard-to-treat genotype 3 hepatitis C.  (April 2015, AIDSmap)
• Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants.  (April 2015, AIDSmap)
• Daclatasvir and Sovaldi Succeed in Those with Advanced Liver Disease.  (April 2015, Hepmag)
• High Hep C Cure Rate for Daclatasvir and Sovaldi in Those With HIV.  (April 2015, Poz)
• Sofosbuvir/ledipasvir plus ribavirin shows high cure rate for hepatitis C patients with advanced liver disease.  (April 2015, AIDSmap)
• Hepatitis C – Both the Good News and Bad.  (March 2015, Beta Blog)
• Sustained virological response represents a long-term cure for people with hepatitis C treated with sofosbuvir.  (March 2015, AIDSmap)
• The benefits of achieving SVR in HCV mono-Infected and HIV/HCV co-infected persons.  (March 2015, Project Inform)
• High SVR rates in HIV/HCV co-infected patients with a fixed-dose regimen of ledipasvir/sofosbuvir.  (March 2015, Project Inform)
• High SVR12 rates seen in HIV/HCV co-infected persons who take daclatasvir with sofosbuvir.  (March 2015, Project Inform)
• Sofosbuvir/ledipasvir raises some antiretroviral levels in HIV/HCV coinfected people.  (March 2015, AIDSmap)
• Pricey New Hep C Drugs Still Cheaper Per Cure Than Oldest Ones.  (March 2015, Hepmag)
• 96% Hep C Cure Rate for Harvoni in Those Coinfected With HIV.  (March 2015, Poz)
• Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection.  (February 2015, AIDSmap)
• 98% Hep C Cure Rate For Harvoni in Those Coinfected With HIV.  (February 2015, Hepmag)
• High Hep Cure Rates for Viekira Pak Among Those Coinfected With HIV.  (February 2015, Hepmag)
• A more personalised approach to hepatitis C treatment may improve adherence and completion rates.  (February 2015, AIDSmap)
• Just One of the Pills in AbbVie’s Hep C Regimen Cures 95% of 1b’s.  (February 2015, Hepmag)
• The 2015 Treatment Landscape for Genotype 1 of Hepatitis C.  (January 2015, Hepmag)
• 2014 Viral Hepatitis Year-in-Review and Looking to 2015.  (January 2015, Hepmag)
• New HCV Option Effective, Safe, Well-Tolerated — and Use Will Likely Be Driven by Payors. (December 2014, Journal Watch)
• Wait a While Before Treating Acute Hepatitis C, Clinic Director Advises.  (December 2014, TheBodyPro)
• Major Pharmacy Group Will Prioritize AbbVie’s Hep C Regimen.  Article daed December 2014, Hepmag)
• FDA Approves AbbVie’s Hepatitis C Regimen Viekira Pak.  (December 2014, Hepmag)
• 2014 AASLD Liver Conference Round-Up.  (December 2014, Hepmag)
• Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis.  (December 2014, AIDSmap)
• Sofosbuvir/ledipasvir with ribavirin cures most people with hepatitis C recurrence after liver transplantation.  (December 2014, AIDSmap)
• Sofosbuvir + simeprevir shows good results for hepatitis C in real-world use.  (December 2014, AIDSmap)
• Sovaldi-Based Hep C Regimens Work Well in the Real World.  (November 2014, Hepmag)
• Five ID/HIV Things to Be Grateful for This Holiday Season, 2014 Edition.   (November 2014, Journal Watch)
• Harvoni Cures Almost All People With Hep C Coinfected With HIV.  (November 2014, Poz)
• 12 Weeks of Harvoni and Ribavirin Cures 96% of Cirrhotics With HCV.  (November 2014, Hepmag)
• Sovaldi and Olysio Cure High Rates of Hep C Post-Liver Transplant.  (November 2014, Hepmag)
• High Success For Harvoni Treating Coinfected Genotype 1.  (November 2014, Hepmag)
• FDA Approves Olysio-Sovaldi Hep C Combo.  (November 2014, Poz)
• Three Deaths on Olysio Lead Japan to Issue Package Warning.  (October 2014, Hepmag)
• Sofosbuvir/ledipasvir safe and effective for genotype 1 HCV.  (October 2014, AIDSmap)
• Fair Pricing Coalition Seeks Uniform Price for Harvoni Treatment.  (October 2014, Hepmag)
• Approval of Sofosbuvir/Ledipasvir Was Expected, but Still Is a Huge Advance.  (October 2014, Journal Watch)
• FDA Approval Notice for Harvoni (Ledipasvir and Sofosbuvir)  (October 2014, U.S. Food and Drug Administration)
• FDA Approves Gilead’s Hep C Drug Harvoni (Ledipasvir/Sofosbuvir)  (October 2014, Poz)
• 8% Don’t Adhere to Sovaldi Hepatitis C Treatment in CVS Study.  (September 2014, Hepmag)
• Sovaldi-Ledipasvir Better Shields the Liver Than Today’s Hep C Meds.  (September 2014, Hepmag)
• Are Fibrosis Tests a Cost-Effective Way to Decide on Hep C Treatment?  (September 2014, Hepmag)
• Curing Hep C Lowers Central Nervous System Fatigue.  (September 2014, Hepmag)
• Hep C Suppression Linked to Major Health Benefits.  (September 2014, Hepmag)
• Selzentry Dosing May Be Inadequate for HIV-Positive Blacks.  (September 2014, Poz)
• New Hep C Drugs Lead to Cancellation of Vertex’s Incivek.  (August 2014, Hepmag)
• New Clinical Guidelines Prioritize Care Among Hep C Patients.  (August 2014, Hepmag)
• Montreal Pilot Program Aims to Cure Homeless of Hepatitis C.  (August 2014, Hepmag)
• Gilead Reaps $3.48 Billion in Second Quarter Sovaldi Sales.  (July 2014, Poz)
• High SVR12 With Sofosbuvir/Ribavirin in HCV/HIV-Coinfected: PHOTON-2.  (July 2014, NATAP)
• Sofosbuvir + ribavirin cures hepatitis C for more than 80% of people with HIV and HCV co-infection.  (July 2014, AIDSmap)
• Sovaldi and Ribavirin Cure High Rates of Those With HIV & Hep C.  (July 2014, Poz)
• CDC Adopts Health IT, Telemedicine to Combat Hepatitis Epidemic.  (June 2014, Hepmag)
• Hep C Decays Faster in Blood Than in the Liver During Treatment.  (July 2014, Hepmag)
• Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation.  (May 2014, AIDSmap)
• Sustained response to treatment reduces fatigue in hepatitis C patients. (May 2014, AIDSmap)
• Sofosbuvir + ribavirin for 24 weeks is highly effective against HCV genotype 4. (May 2014, AIDSmap)
• Sofosbuvir for hepatitis C works well despite multiple negative predictive factors.  (April 2014, AIDSmap)
• Sofosbuvir + ribavirin is safe and effective for people with hepatitis C who have advanced liver disease.  (April 2014, AIDSmap)
• Sofosbuvir + simeprevir dual therapy shows high cure rates for hepatitis C patients with or without cirrhosis. (April 2014, AIDSmap)
• 88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy.  (April 2014, AIDSmap)
• Lawmakers Attack High Price of Gilead’s Hep C Drug Sovaldi.  (March 2014, Poz)
• Sovaldi & Ribavirin Is Effective for HIV/HCV Population.  (March 2014, Poz)
• Sofosbuvir With Ribavirin in Gt1/2/3 HCV/HIV Coinfected Patients. (March 2014, NATAP)
• Sofosbuvir & ribavirin cures 75% of genotype 1 HIV/HCV co-infected patients.  (March 2014, AIDSmap)
• Simeprevir cures almost 80% of first-time co-infected hepatitis C patients.  (March 2014, AIDSmap)
• Simeprevir Plus PegIFN/RBV Yields 74% SVR12 in HCV/HIV Patients. (March 2014, NATAP)
• HIV No Bar to HCV Therapy With New Agents. (March 2014, MedPage Today)
• U.S. medical societies launch new hepatitis C treatment guidelines Hepatitis C treatment. (January 2014, AIDSmap)
• Low lymphocyte count a risk factor for infections for people taking HCV therapy.  (January 2014, AIDSmap)